Structure and function of Factor VIII

  • Pete Lollar
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)


When the first International Symposium on Inhibitors was held 10 years ago, the existing knowledge of Factor VIII (F.VIII) structure and function was summarized by Fulcher and Zimmerman.1 F.VIII had been recently purified from bovine, porcine, and human plasma, and investigators interested in the biochemistry of F.VIII were at the threshold of making significant progress. This followed a decade of frustrating work in which advances in protein purification and immunological methods had made the purification of F.VIII a feasible but elusive goal.


Factor VIII Procoagulant Activity Coagulation Factor VIII Human Factor VIII Tyrosine Sulfation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fulcher, CA., and T.S. Zimmerman. 1984. Structure and function of factor VIII coagulant protein. In Factor VIII Inhibitors. L.W. Hoyer, editor. Alan R. Liss, New York. 57#x2013;72.Google Scholar
  2. 2.
    Toole, J.J., J.L. Knopf, J.M. Wozney, LA. Sultzman, J.L. Buecker, D.D. Pittman, RJ. Kaufman, E. Brown, C. Shoemaker, E.C. Orr, G.W. Amphlett, W.B. Foster, M.L. Coe, G.J. Knutson, D.N. Fass, and R.M. Hewick. 1984. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature312: 342#x2013;347.PubMedCrossRefGoogle Scholar
  3. 3.
    Gitschier, J, W.I. Wood, T.M. Goralka, K.L. Wion, E.Y. Chen, D.H. Eaton, G.A. Vehar, D.J. Capon, and R.M. Lawn. 1984. Characterization of the human factor VIII gene. Nature12:326–330.CrossRefGoogle Scholar
  4. 4.
    Vehar, G.A., B. Keyt, D. Eaton, H. Rodriguez, D.P. O’Brien, F. Rotblat, H. Oppermann, R. Keck, W.I. Wood, R.N. Harkins, E.G.D. Tuddenham, R.M. Lawn, and DJ. Capon. 1984. Structure of human factor VIII. Nature312: 337#x2013;342.PubMedCrossRefGoogle Scholar
  5. 5.
    Fass, D.N., G.J. Knutson, and J.A. Katzmann. 1982. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood59: 594#x2013;600.PubMedGoogle Scholar
  6. 6.
    Fay, P.J., M.T. Anderson, S.I. Chavin, and V.J. Marder. 1986. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim. Biophys Acta871: 268#x2013;278.PubMedCrossRefGoogle Scholar
  7. 7.
    Nesheim, M.E., K.H. Myrmel, L. Hibbard, and K.G. Mann. 1979. Isolation and characterization of single chain bovine factor V. J.Biol.Chem.254: 508#x2013;517.PubMedGoogle Scholar
  8. 8.
    Kaufman, R.J., L.C. Wasley, and A.J. Dorner. 1988. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol.Chem.263: 6352#x2013;6362.PubMedGoogle Scholar
  9. 9.
    Eaton, D.L., RE. Hass, L. Riddle, J. Mather, M. Wiebe, T. Gregory, and G.A. Vehar. 1987. Characterization of recombinant human factor VIII. J. Biol.Chem.262: 3285#x2013;3290.PubMedGoogle Scholar
  10. 10.
    Eaton, D., H. Rodriguez, and G.A. Vehar. 1986. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry25: 505#x2013;512.PubMedCrossRefGoogle Scholar
  11. 11.
    Eaton, D.L., W.I. Wood, D. Eaton, P.E. Hass, P. Hollingshead, K. Wion, J. Mather, R.M. Lawn, G.A. Vehar, and C. Gorman. 1986. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry25: 8343#x2013;8347.PubMedCrossRefGoogle Scholar
  12. 12.
    Fay, P.J., T.M. Smudzin, and F.J. Walker. 1991. Activated protein C-catalyzed inactivation of human factor VIII and factor Villa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J.Biol.Chem.266: 20139#x2013;20145.PubMedGoogle Scholar
  13. 13.
    Lamphear, B.J., and PJ. Fay. 1992. Proteolytic interactions of factor IXa with human factor VIII and factor Villa. Blood80: 3120#x2013;3128.PubMedGoogle Scholar
  14. 14.
    O’Brien, D.P., D.Johnson, P. Byfield, and E.G.D. Tuddenham. 1992. Inactivation of factor VIII by factor IXa. Biochemistry 31:2805–2812.Google Scholar
  15. 15.
    Elder, B.,D. Lakich, and J. Gitschier. 1993. Sequence of the murine factor VIH cDNA. Genomics16: 374#x2013;379.CrossRefGoogle Scholar
  16. 16.
    Toole, J.J., D.D. Pittman, E.C. Orr, P. Murtha, L.C. Wasley, and RJ. Kaufman. 1986. A large region (approximately equal to 95 kDa) of human factor VIII is dispensible for in vitro procoagulant activity. Proc. Natl Acad. Sci. USA83: 5939#x2013;5942.PubMedCrossRefGoogle Scholar
  17. 17.
    Leyte, A., H.B. van Schijndel, C. Neihrs, W.B. Huttner, M.P. Verbeet, K. Mertens, and J.A. van Mourik. 1991. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J.Biol. Chem.266: 740#x2013;746.PubMedGoogle Scholar
  18. 18.
    Andersson, L.O., N. Forsman, K. Huang, K. Larsen, A. Lundin, B. Pavlu, J. Sandberg, K. Sewerin, and J. Smart. 1986. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc. Natl. Acad. Sci. USA83: 2979#x2013;2983.PubMedCrossRefGoogle Scholar
  19. 19.
    Lollar, P., C.G. Parker, and R.P. Tracy. 1988. Molecular characterization of commercial porcine factor VIII concentrate. Blood71: 137#x2013;143.PubMedGoogle Scholar
  20. 20.
    Mosesson, M.W., D.N. Fass, P. Lollar, J.P. DiOrio, C.G. Parker, G.J. Knutson, J.F. Hainfeld, and J.S. Wall. 1990. Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and stem mass analysis. J. Clin. Invest.145: 1310#x2013;1311.Google Scholar
  21. 21.
    Fowler, W.E., P.J. Fay, D.S. Arvan, and V.J. Marder. 1990. Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments. Proc. Natl. Acad. Sci. USA87: 7648#x2013;7652.PubMedCrossRefGoogle Scholar
  22. 22.
    Lollar, P., and C.G. Parker. 1987. Stoichiometry of the porcine factor VIII-von Willebrand factor association. J. Biol Chem.262: 17572#x2013;17576.PubMedGoogle Scholar
  23. 23.
    Lollar, P., and C.G. Parker. 1989. Subunit structure of thrombin-activated porcine factor VIII. Biochemistry28: 666#x2013;674.PubMedCrossRefGoogle Scholar
  24. 24.
    Jenny, R.J., D.D. Pittman, J.J. Toole, R.W. Kriz, R.A. Aldape, R.M. Hewick, RJ. Kaufman, and K.G. Mann. 1987. Complete cDNA and derived amino acid sequence of human factor V. Proc. Natl Acad. Sci. USA84: 4846#x2013;4850.PubMedCrossRefGoogle Scholar
  25. 25.
    Kane, W.H., and E.W. Davie. 1988. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood71: 539#x2013;555.PubMedGoogle Scholar
  26. 26.
    Dorner, A.J., D.G. Bole, and R.J. Kaufman. 1987. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J. Cell Biol.105: 2665#x2013;2674.PubMedCrossRefGoogle Scholar
  27. 27.
    Pittman, D.D., J.H. Wang, and R.J. Kaufman. 1992. Identification and functional importance of tyrosine sulfate residues within recombinant human factor VIII. Biochemistry31: 3315#x2013;3325.PubMedCrossRefGoogle Scholar
  28. 28.
    Curtis, J.E., S.L. Helgerson, E.T. Parker, and P. Lollar. 1994. Isolation and characterization of thrombin-activated human factor VIII. J. Biol. Chem.269: 6246#x2013;51.PubMedGoogle Scholar
  29. 29.
    Tuddenham, E.G., R.S. Lane, F. Rotblat, A.J. Johnson, T.J. Snape, S. Middleton, and P.B. Kernoff. 1982. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand’s disease. Br. J. Haematol.52: 259#x2013;267.PubMedCrossRefGoogle Scholar
  30. 30.
    Brinkhous, K.M., H. Sandberg, J.B. Garris, C. Mattson, M. Palm, T. Griggs, and M.S. Read. 1985. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusion into hemophilic and von Willebrand disease dogs. Proc. Natl Acad. Sci. USA82: 8752#x2013;8755.PubMedCrossRefGoogle Scholar
  31. 31.
    Fass, D.N., GJ. Knutson, and EJ. Bowie. 1978. Porcine Willebrand factor: a population of murtimers. J. Lab. Clin. Med.91: 307#x2013;320.PubMedGoogle Scholar
  32. 32.
    Chopek, M.W., J.P. Girma, K. Fujikawa, E.W. Davie, and K. Titani. 1986. Human von Willebrand factor: a multivalent protein composed of identical subunits. Biochemistry25: 3146#x2013;3155.PubMedCrossRefGoogle Scholar
  33. 33.
    Wagner, D.D. 1990. Cell biology of von Willebrand factor. Ann. Rev. Cell Biol.6: 217#x2013;246.PubMedCrossRefGoogle Scholar
  34. 34.
    Fretto, L.J., WE. Fowler, D.R. McCaslin, H.P Erickson, and P.A. McKee. 1986. Substructure of human von Willebrand factor. Proteolysis by V8 and characterization of two functional domains. J. Biol. Chem.261: 15679#x2013;15689.PubMedGoogle Scholar
  35. 35.
    Fowler, W.E., LJ. Fretto, K.K. Hamilton, H.P. Erickson, and P.A. McKee. 1985. Substructure of human von Willebrand factor, J. Clin. Invest.76: 1491#x2013;1500.PubMedCrossRefGoogle Scholar
  36. 36.
    Ohmori, K., L.J. Fretto, R.L. Harrison, M.E. Switzer, H.P. Erickson, and P.A. McKee. 1982. Electron microscopy of human factor VIII/von Willebrand glycoprotein: effect of reducing reagents on structure and function, J. Cell Biol.95: 632#x2013;640.PubMedCrossRefGoogle Scholar
  37. 37.
    Slayter, H., J. Loscalzo, P. Bockenstedt, and R.I. Handin. 1985. Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering. J. Biol. Chem.260: 8559#x2013;8563.PubMedGoogle Scholar
  38. 38.
    Foster, P.A., CA. Fulcher, T. Marti, K. Titani, and T.S. Zimmerman. 1987. A major factor VIII binding domain resides within the ammo-terminal 272 residues of von Willebrand factor. J. Biol. Chem.262: 8443#x2013;8446.PubMedGoogle Scholar
  39. 39.
    Bahou, W.F., D. Ginsburg, R. Sikkink, R. Litwiller, and D.N. Fass. 1989. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding: Localization of its antigenic determinant to a nonadecapeptide at the animoterrninus of the mature vWF polypeptide. J. Clin. Invest.84: 56#x2013;61.PubMedCrossRefGoogle Scholar
  40. 40.
    Ginsburg, D., and E.J.W. Bowie. 1992. Molecular genetics of von Willebrand disease. Blood79: 2507#x2013;2519.PubMedGoogle Scholar
  41. 41.
    Owen, W.G., and R.H. Wagner. 1972. Antihemophilic factor: separation of an active fragment following dissociation by salts or detergents. Thromb Diath. Haemorrh.27: 502#x2013;515.PubMedGoogle Scholar
  42. 42.
    Weiss, HJ., and L.W. Hoyer. 1973. Von Willebrand factor: dissociation from antihemophilic factor activity. Science182: 1149#x2013;1151.PubMedCrossRefGoogle Scholar
  43. 43.
    Zucker, M.B., M.E. Soberano, AJ. Johnson, AJ. Fulton, S. Kowalski, and M. Adler. 1983. The in vitro association of antihemophilic factor and von Willebrand factor. Thromb. Haemostas.49: 37#x2013;41.Google Scholar
  44. 44.
    Leyte, A., M.P. Verbeet, T. Brodniewicz-Proba, J.A. van Mourik, and K. Mertens. 1989. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Biochem. J.257: 679#x2013;683.PubMedGoogle Scholar
  45. 45.
    Nesheim, M., D.D. Pittman, A.R. Giles, D.N. Fass, J.H. Wang, D. Slonosky, and RJ. Kaufman. 1991. The effect of plasma von Willebrand factor on the binding of human factor VIII to human platelets. J. Biol Chem.266: 17815#x2013;17820.PubMedGoogle Scholar
  46. 46.
    Foster, P.A., C.A. Fulcher, R.A. Houghten, and T.S. Zimmerman. 1988. An immunogenic region with residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J. Biol Chem.263: 5230#x2013;5234.PubMedGoogle Scholar
  47. 47.
    Lollar, P., D.C. Hill-Eubanks, and G.G. Parker. 1988. Association of the factor VIII light chain with von Willebrand factor. J. Biol Chem.263: 10451#x2013;10455.PubMedGoogle Scholar
  48. 48.
    Hamer, R.J., J.A. Koedam, N.H. Beeser-Visser, and J J. Sixma. 1987. The effect of thrombin on the complex between factor VIII and von Willebrand factor. Eur. J. Biochem.167: 253#x2013;259.PubMedCrossRefGoogle Scholar
  49. 49.
    Leyte, A., K. Mertens, B. Distel, R.F. Evers, M.J.M. De Keyzer-Nellen, M.M.C.L. Groenen-van Dooren, J.D.E. de Bruin, H. Pannekoek, J.A. van Mourik, and M.P. Verbeet. 1989. Inhibition of human coagulation Factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant Factor VIII fragments. Biochem. J.263: 187#x2013;194.PubMedGoogle Scholar
  50. 50.
    Precup, J.W., B.C. Kline, and D.N. Fass. 1991. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage. Blood77: 1929#x2013;1936.PubMedGoogle Scholar
  51. 51.
    Shima, M., D. Scandella, A. Yoshioka, H. Nakai, I. Tanaka, S. Kamisue, S. Terada, and H. Fukui. 1993. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit binding to von Willebrand factor and to phosphatidylserine. Thromb. Haemostas.69: 240#x2013;246.Google Scholar
  52. 52.
    Lollar, P., G.J. Knutson, and D.N. Fass. 1985. Activation of porcine factor VIII:C by thrombin and factor Xa. Biochemistry24: 8056#x2013;8064.PubMedCrossRefGoogle Scholar
  53. 53.
    Neuenschwander, P., and J. Jesty. 1992. Thrombin-activated and factor Xa-activated human factor VIII: differences in cofactor activity and decay rate. Arch. Biochem. Biophys.296: 426#x2013;434.PubMedCrossRefGoogle Scholar
  54. 54.
    Hultin, M.B., and J. Jesty. 1981. The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin. Blood57: 476#x2013;482.PubMedGoogle Scholar
  55. 55.
    Lollar, P., GJ. Knutson, and D.N. Fass. 1984. Stabilization of thrombin-activated porcine factor VIILC by factor IXa and phospholipid. Blood63: 1303#x2013;1308.PubMedGoogle Scholar
  56. 56.
    Cooper, H.A., F.F. Reisner, M. Hall, and R.H. Wagner. 1975. Effects of thrombin treatment on preparations of factor VIII and the Ca2+-dissociated small active fragment. J. Clin. Invest.56: 751#x2013;760.PubMedCrossRefGoogle Scholar
  57. 57.
    Weiss, HJ., and S. Kochwa. 1970. Molecular forms of antihemophilic globulin in plasma, cryoprecipitate, and after thrombin activation. Br. J. Haematol.18: 89#x2013;100.PubMedCrossRefGoogle Scholar
  58. 58.
    Hill-Eubanks, D.C, CG. Parker, and P. Lollar. 1989. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc. Natl Acad. Sci. USA86: 6508#x2013;6512.PubMedCrossRefGoogle Scholar
  59. 59.
    Aly, A.M., and L.W Hoyer. 1992. Factor VIII-East Hartford has procoagulant activity when separated from von Willebrand factor. J. Clin. Invest.89: 1382#x2013;1387.PubMedCrossRefGoogle Scholar
  60. 60.
    O’Brien, D.P., J.K. Patinson, and E.G.D. Tuddenham. 1990. Purification and characterization of factor VIII 372-Cys: A hypofunctional cofactor from a patient with moderately severe hemophilia A. Blood75: 1664 - 1672.PubMedGoogle Scholar
  61. 61.
    Pittman, D.D., and RJ. Kaufman. 1988. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc. Natl. Acad. Sci. USA85: 2429#x2013;2433.PubMedCrossRefGoogle Scholar
  62. 62.
    Hill-Eubanks, D.C., and P. Lollar. 1990. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J. Biol. Chem. 265:17854–17858.PubMedGoogle Scholar
  63. 63.
    Barrow, R.T., J.F. Healey, and P. Lollar. 1994. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex. J. Biol. Chem.269: 593#x2013;8.PubMedGoogle Scholar
  64. 64.
    Fay, P.J., PJ. Haidaris, and T.M. Smudzin. 1991. Human factor VIIIa subunit structure: reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J. Biol. Chem.266: 8957#x2013;8962.PubMedGoogle Scholar
  65. 65.
    Lollar, P., and E.T. Parker. 1991. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J. Biol. Chem.266: 12481#x2013;12486.PubMedGoogle Scholar
  66. 66.
    Lollar, P., E.T. Parker, and PJ. Fay. 1992. Coagulant properties of hybrid human/ porcine factor VIII molecules. J. Biol Chem.267: 23652#x2013;23657.PubMedGoogle Scholar
  67. 67.
    . Lollar, P., and C.G. Parker. 1990. pH-dependent denaturation of thrombin-activated porcine factor VIII. J. Biol Chem. 265:1688–1692.PubMedGoogle Scholar
  68. 68.
    Hemker, H.C., and MJ.P. Kahn. 1967. Reaction sequence of blood coagulation. Nature215: 1201#x2013;1202.PubMedCrossRefGoogle Scholar
  69. 69.
    van Dieijen, G., G. Tans, J. Rosing, and H.C. Hemker. 1981. The role of phospholipid and factor VIIIa in the activation of bovine factor X J. Biol Chem. 256: 3433#x2013;3442.PubMedGoogle Scholar
  70. 70.
    Duffy, E J., and P. Lollar. 1992. Intrinsic pathway activation of factor X and its activation peptide-deflcient derivative, factor X(Des 143.191). J. Biol. Chem.267: 7821#x2013;7827.PubMedGoogle Scholar
  71. 71.
    Rosing, J., G. Tans, J.W.P. Govers-Riemslag, R.F.A. Zwaal, and H.C. Hemker. 1980. The role of phospholipids and factor Va in the prothrombinase complex. J. Biol Chem.255: 274#x2013;283.PubMedGoogle Scholar
  72. 72.
    Duffy, E J., E.T. Parker, VP Mutucumarana, A.E. Johnson, and P. Lollar. 1992. Binding of factor Villa and factor VIII to factor IXa on phospholipid vesicles. J. Biol Chem.267: 17006#x2013;17011.PubMedGoogle Scholar
  73. 73.
    Mutucumarana, VP, E J. Duffy, P. Lollar, and A.E. Johnson. 1992. The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study. J. Biol. Chem.267: 17012#x2013;17021.PubMedGoogle Scholar
  74. 74.
    Husten, E J., CT. Esmon, and A.E. Johnson. 1987. The active site of blood coagulation factor Xa. Its distance from the phospholipid surface and its conformational sensitivity to components of the prothrombinase complex. J. Biol. Chem.262: 12953#x2013;12961.PubMedGoogle Scholar
  75. 75.
    Zwaal, R.F.A., P. Comfurius, and L.LM. van Deenen. 1977. Membrane asymmetry and blood coagulation. Nature268: 358#x2013;360.PubMedCrossRefGoogle Scholar
  76. 76.
    Lajmanovich, A., G. Hudry-Clergeon, J.M. Freyssinet, and G. Marguerie. 1981. Human Factor VIII procoagulant activity and phospholipid interactions. Biochem. Biophys. Acta678: 132#x2013;136.PubMedGoogle Scholar
  77. 77.
    Andersson, L.O., and J.E. Brown. 1981. Interaction of Factor VIII-von Willebrand Factor with phospholipid vesicles. Biochem. J.200: 161#x2013;167.PubMedGoogle Scholar
  78. 78.
    Koedam, J.A., RJ. Hamer, N.H. Beeser-Visser, B.N. Bouma, and J.J. Sixma. 1990. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur. J. Biochem.189: 229#x2013;234.PubMedCrossRefGoogle Scholar
  79. 79.
    Koedam, J.A., J.CM. Meijers, J.J. Sixma, and B.N. Bouma. 1988. Inactivation of human factor-VIII by activated protein-C. Cofactor activity of protein-S and protective effect of von Willebrand factor. J. Clin. Invest.82: 1236#x2013;1243.PubMedCrossRefGoogle Scholar
  80. 80.
    . Fay, PJ., J.-V. Coumans, and F.J. Walker. 1991. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J. Biol. Chem. 266:2172–2177.PubMedGoogle Scholar
  81. 81.
    Rick, M.E., N.L. Esmon, and D.M. Krizek. 1990. Factor IXa and von Willebrand factor modify the inactivation of factor VIII by activiated protein C. J. Lab. Clin. Med.115: 415#x2013;421.PubMedGoogle Scholar
  82. 82.
    Bloom, J.W. 1987. The interaction of rDNA factor VIII, factor VIIIses-797-1562, and factor VIIIses-797-1562-derived peptides with phospholipid. Thromb. Res.48: 439#x2013;448.PubMedCrossRefGoogle Scholar
  83. 83.
    Gilbert, G.E., B.C. Furie, and B. Furie. 1990. Binding of human factor VIII to phospholipid vesicles, J. Biol. Chem.265: 815#x2013;822.PubMedGoogle Scholar
  84. 84.
    Gilbert, G.E., D. Drinkwater, S. Barter, and S.B. Clouse. 1992. Specificity of phosphatidylserine-containing membrane binding sites for factor VIII. J. Biol Chem.267: 15861#x2013;15868.PubMedGoogle Scholar
  85. 85.
    Gilbert, G.E., and D. Drinkwater. 1993. Specific membrane binding of factor VIII is mediated by sO-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry32: 9577#x2013;9585.PubMedCrossRefGoogle Scholar
  86. 86.
    Foster, P.A., CA.. Fulcher, R.A. Houghten, and T.S. Zimmerman. 1990. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood75: 1999#x2013;2004.PubMedGoogle Scholar
  87. 87.
    Scandella, D., S.D. Mahoney, M. Mattingly, D. Roeder, L. Timmons, and C.A. Fulcher. 1988. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia Coli. Proc. Natl Acad. Sci. USA85: 6152#x2013;6156.PubMedCrossRefGoogle Scholar
  88. 88.
    Arai, M., D. Scandella, and L.W. Hoyer. 1989. Molecular basis of factor-VIII inhibition by human antibodies - antibodies that bind to the factor-VIII light chain prevent the interaction of factor-VIII with phospholipid. J. Clin. Invest.83: 1978#x2013;1984.PubMedCrossRefGoogle Scholar
  89. 89.
    Guinto, E.R., and CT. Esmon. 1984. Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J. Biol. Chem.259: 13986#x2013;13992.PubMedGoogle Scholar
  90. 90.
    Luckow, E.A., D.A. Lyons, T.M. Ridgeway, CT. Esmon, and T.M. Laue. 1989. Interaction of clotting factor V heavy chain with prothrombin and prethrombin 1 and role of activated protein C in regulating this interaction: analysis by analytical ultracentrifugation. Biochemistry28: 2348#x2013;2353.PubMedCrossRefGoogle Scholar
  91. 91.
    Fay, P.J., P.J. Haidaris, and CF. Huggins. 1993. Role of the COOH-terminal acidic region of Al subunit in A2 subunit retention in human factor VIIIa, J. Biol Chem.268: 17861#x2013;17866.PubMedGoogle Scholar
  92. 92.
    Walker, F.J., D. Scandella, and P.J. Fay. 1990. Identification of the binding site for activated protein C on the light chain of factors V and VIII. J. Biol Chem.265: 1484#x2013;1489.PubMedGoogle Scholar
  93. 93.
    Lollar, P., and D.N. Fass. 1984. Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone. Arch. Biochem. Biophys.233: 438#x2013;446.PubMedCrossRefGoogle Scholar
  94. 94.
    Lamphear, B.J., and P.J. Fay. 1992. Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer. J. Biol. Chem.267: 3725#x2013;3730.PubMedGoogle Scholar
  95. 95.
    Lollar, P., E.T. Parker, J.E. Curtis, S.L. Helgerson, L.W. Hoyer, M.E. Scott, and D. Scandella. 1994. Inhibition of human factor Villa by anti-A2 subunit antibodies, J. Clin. Invest, submittedGoogle Scholar
  96. 96.
    Gilles, J.G.G., J. Arnout, J. Vermylen, and J.-M.R. Saint-Remy. 1993. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood82: 2452#x2013;2461.PubMedGoogle Scholar
  97. 97.
    . Lubin, I.M., J.F. Healey, P. Lollar, D. Scandella, and M.S. Runge. 1993. Expression of a recombinant hybrid human/porcine factor VIII molecule with elimination of reactivity toward an inhibitory anti-human A2 domain antibody. Blood82a:in press.Google Scholar
  98. 98.
    Ware, J., M.J. MacDonald, M. Lo, S. de Graaf, and CA. Fulcher. 1992. Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide. Blood Coagul. Fibrinolysis.3: 703#x2013;716.PubMedCrossRefGoogle Scholar
  99. 99.
    Scandella, D., M. Mattingly, and R. Prescott. 1993. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies which bind to A2. Blood82:1767–1775.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Pete Lollar
    • 1
  1. 1.Division of Hematology-Oncology, Department of MedicineEmory UniversityAtlantaUSA

Personalised recommendations